Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions post-allogeneic bone marrow transplantation

Bone Marrow Transplantation

Volumn 18, Issue 6, 1996, Pages 1153-1156

  Kapelushnik, J ^a   Nagler, A ^a   Or, R ^a   Naparstek, E ^a   Ackerstein, A ^a   Samuel, S ^a   Morecki, S ^a   Nabet, C ^a   Slavin, S ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Activated allogeneic cell therapy; BMT; CML

Indexed keywords

BCR ABL PROTEIN; RECOMBINANT INTERLEUKIN 2;

ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD CELL; BLOOD TRANSFUSION; CASE REPORT; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; EFFECTOR CELL; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; KARYOTYPE; MALE; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; HUMANS; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LEUKEMIA, MYELOID, AGGRESSIVE-PHASE; LEUKOCYTE TRANSFUSION; LYMPHOCYTE ACTIVATION; MALE; RECOMBINANT PROTEINS; RECURRENCE; SALVAGE THERAPY; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030444337     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Fialkow PJ, Gartler SM, Yoshida A. Clonal origin of chronic myelogenous leukemia in man. Proc Natl Acad Sci USA 1967; 58: 1968-1971.
2. Heisterkamp N, Stephenson JR, Groffen J et al. Localization of the C-abl oncogene adjacent to translocation. Breakpoint in chronic myelocytic leukaemia. Nature (London) 1983; 306: 239-242.
3. McGlave P. Bone marrow transplants in chronic myelogenous leukemia: an overview of determinants of survival. Semin Hematol 1990; 27: 23-30.
4. Verfallie C, Miller W, Kay N, McGlave P. Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity. Blood 1989; 74: 793-797.
5. Verfaillie C, Kay N, Miller W, McGlave P. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia. Blood 1990; 76: 401-408.
6. Hauch M, Gazzola MV, Small T et al. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 1990; 75: 2250-2262.
7. Morecki S, Revel-Vilk S, Nabet C et al. Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-α2a and interleukin-2. Cancer Immuno Immunother 1992; 35: 401-411.
8. Nagler A, Ackerstein A, Barak V, Slavin S. Treatment of chronic myelogenous leukemia with recombinant human interleukin-2 and α-interferon. J Hematother 1994; 3: 75-82.
9. Slavin S, Or R, Kapelushnik J et al. Immunotherapy of minimal residual disease in conjunction with autologous and allogeneic bone marrow transplantation (BMT). Leukemia 1992; 6: 164-166.
10. Slavin S, Naparstek E. Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post-allogenic bone marrow transplantation. Blood 1996; 87: 2195-2204.
11. Naparstek E, Or R, Nagler A et al. T cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 1995; 89: 506-515.
12. Kolb HJ, Mittermueller J, Clemm CH et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
13. Bar BM, Schattenberg A, Mensink E et al. Donor leukocyte infusions for chronic myeloid leukemia relapse after allogeneic bone marrow transplantation. J Clin Oncol 1993; 11: 513-519.
14. Jiang YZ, Cullis JO, Kanfer EJ et al. T cell and NK cell mediated graft-versus-leukemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 1993; 11: 133-138.
15. Drobyski WR, Keever CA, Roth SK et al. Salvage immunotherapy using donor leukocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310-2318.
16. Antin HJ. Graft-versus-leukemia: no longer an epiphenomenon. Blood 1993; 82: 2273-2277.
17. Porter DL, Roth MS, McGarigle C et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. New Engl J Med 1994; 330: 100-106.
18. Kolb HJ, de Witte T. Mittermuller J et al. Graft-versus-leukemia effect of donor buffy coat transfusions on recurrent leukemia after marrow transplantation. Clin Blood 1993; 82: (Suppl.1): 214a (Abstr. 840).
19. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy for relapsed leukemia following allogeneic bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995; 23: 1553-1562.
20. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
21. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T cell depletion. Ann Intern Med 1988; 108: 806-814.
22. Roth MS, Antin JH, Ash R et al. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood 1992; 79: 276-282.
23. Phillips JH, Lanier LL. Dissection of the lymphokine-activated killer phenomenon: relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 1986; 164: 814-825.
24. Trinchieri G, Matsumoto-Kobayashi M, Clark SC et al. Response of resting human peripheral blood natural killer cells to interleukin-2. J Exp Med 1984; 160: 1147-1155.
25. Slavin S, Ackerstein A, Weiss L. Adoptive immunotherapy in conjunction with bone marrow transplantation-amplification of natural host defense mechanisms against cancer by recombinant IL-2. Natl Immun Cell Growth Regul 1988; 7: 180-184.
26. Ackerstein A, Kedar E, Slavin S. Use of recombinant interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematological disorders. Blood 1991; 78: 1212-1215.
27. Foa R, Flerro MT, Tosti S et al. Induction and persistence of complete remission in a resistant acute myeloid leukemia patient after treatment with recombinant interleukin-2. Leuk Lymphoma 1990; 1: 113-116.
28. Rosenberg SA, Mule JJ, Spiess PJ. Regression of established pulmonary metastasis and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 1985; 161: 1169-1173.
29. Dutcher JP, Greekmore S, Weiss GR et al. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 1989; 7: 477-484.
30. Rosenberg SA, Lotze MT, Mul LM et al. Progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. New Engl J Med 1987; 316: 889-897.
31. Phillips JH, Gemlo BT, Myers WW et al. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy. J Clin Oncol 1987; 5: 1933-1941.
32. MacKinnon S, Hows JM, Goldman JM. Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia. Blood 1990; 76: 2037-2045.
33. Cohen P, Vourka-Karussis U, Weiss L, Slavin S. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor and host-specific allo-antigens. J Immunol 1993; 151: 4803-4810.
34. Vourka-Karussis U, Karussis D, Ackerstein A, Slavin S. Enhancement of graft-versus-leukemia effect (GVL) with recombinant human interleukin-2 (rIL-2) following bone marrow transplantation in a murine model for acute myeloid leukemia in SJL/J mice. Exp Hematol 1995; 23: 195-201.